The CBCE (Center for Biomedical Continuing Education)
Ultima Vez Modificado: 4 de agosto del 2006
Conference Dates: November 4, 2006
Conference Location: Philadelphia, PA
Sponsoring Group: The CBCE (Center for Biomedical Continuing Education)
Conference Web Page URL: www.thecbce.om
Topics Covered: For many solid tumors, the treatment of choice is often surgical resection followed by radiation therapy, with or without chemotherapy, depending on the performance status of the patient. However, patient prognosis even after these interventions remains poor, and therapy is often accompanied by severe toxicity. More effective and less toxic therapies are needed. As the molecular details of tumor growth, angiogenesis, and progression become known, novel agents that target these pathways are being developed. These novel agents are being investigated as possible radiotherapy sensitizers, and clinical trials to date suggest a place for these agents in combined-modality treatment regimens for some solid tumors. This meeting will serve as a forum for opinion leaders to discuss emerging data on the appropriate use of targeted and cytotoxic therapies in combined-modality treatment regimens of solid tumors.
Conference Objectives: Please see www.thecbce.com for further information.
Who Should Attend: Medical oncologists, surgical oncologists, radiation oncologists, and other healthcare providers who have an interest in the biology, diagnosis, and treatment of cancer
Conference Agenda: Please see www.thecbce.com for further information
Registration Information: Please see www.thecbce.com for further information
Conference Fees: Please see www.thecbce.com for further information
Continuing Education: YesEnglish
Sep 2, 2014 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.
Sep 2, 2014
Feb 9, 2011
Mar 17, 2010